Dori Pelled
Operationeel Directeur bij Imel Biotherapeutics, Inc.
Profiel
Dori Pelled is currently the Chief Operating Officer at Imel Biotherapeutics, Inc. He previously worked as the CTO & Director-Clinical Research at Enzymotec Ltd.
and as the Vice President-Operations at Eloxx Pharmaceuticals, Inc. He received his undergraduate and graduate degrees from Tel-Aviv University and his doctorate from Weizmann Institute of Science.
Actieve functies van Dori Pelled
Bedrijven | Functie | Begin |
---|---|---|
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Operationeel Directeur | 01-03-2019 |
Eerdere bekende functies van Dori Pelled
Bedrijven | Functie | Einde |
---|---|---|
ELOXX PHARMACEUTICALS, INC. | Operationeel Directeur | 25-06-2018 |
ENZYMOTEC LTD. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Dori Pelled
Tel-Aviv University | Graduate Degree |
Weizmann Institute of Science | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ELOXX PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Enzymotec Ltd.
Enzymotec Ltd. BiotechnologyHealth Technology Enzymotec Ltd. develops and manufactures bio functional ingredients for health needs. The company was founded on March 8, 1998 and is headquartered in Migdal HaEmeq, Israel. | Health Technology |
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Commercial Services |